

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

October 30, 2017

Rostislav Raykov Chief Executive Officer Fennec Pharmaceuticals Inc. PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709

> Re: Fennec Pharmaceuticals Inc. Registration Statement on Form S-3 Filed October 24, 2017 File No. 333-221093

Dear Mr. Raykov:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at (202) 551-6761 with any questions.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Garett Sleichter